The transaction grants Aurora direct ownership of a licensed import and wholesale facility alongside a virtual pharmacy operation. By integrating these assets, the company aims to bypass third-party distributors and streamline the delivery of its medical-grade products to patients across the United Kingdom. Aurora CEO Miguel Martin stated that the acquisition provides the necessary agility to respond to rising patient demand and increasingly stringent regulatory standards.
In section Releases
Aurora Cannabis Expands UK Footprint with Double Acquisition
Canadian medical cannabis giant Aurora Cannabis has acquired Birmingham-based Internode Pharma Limited and HAP Pharma Limited in a move to seize greater control over its UK supply chain. The deal, valued at 2.1 million British pounds, marks a strategic push to capture market share in Europe’s largest medical cannabis sector.
Financial projections suggest the move will be accretive to adjusted EBITDA in future quarters as the company reduces its reliance on external logistics. With a population of 70 million, the UK remains a priority for Aurora’s international growth strategy. The company is already evaluating further investments to bolster its distribution capacity, signaling a commitment to a medical-first approach in the region.
Comments (0)
No comments yet. Be the first!